National Institute for Health and Care Excellence (NICE)
- Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated.
- Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy.
- Panobinostat for treating multiple myeloma after at least 2 previous treatments.
- Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases.